|
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS) DCF Valoración |
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS) Bundle
Diseñada para la precisión, nuestra calculadora DCF (603456SS) le permite evaluar la valoración de Zhejiang Jiuzhou Pharmaceutical Co., Ltd utilizando datos financieros del mundo real y ofrece una flexibilidad completa para modificar todos los parámetros clave para mejorar las proyecciones.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,016.8 | 2,647.3 | 4,063.2 | 5,445.1 | 5,523.4 | 5,571.4 | 5,619.8 | 5,668.6 | 5,717.9 | 5,767.5 |
| Revenue Growth, % | 0 | 31.26 | 53.48 | 34.01 | 1.44 | 0.86868 | 0.86868 | 0.86868 | 0.86868 | 0.86868 |
| EBITDA | 487.8 | 744.8 | 1,062.4 | 1,477.8 | 1,597.3 | 1,499.0 | 1,512.0 | 1,525.1 | 1,538.4 | 1,551.8 |
| EBITDA, % | 24.19 | 28.13 | 26.15 | 27.14 | 28.92 | 26.91 | 26.91 | 26.91 | 26.91 | 26.91 |
| Depreciation | 192.5 | 252.8 | 292.3 | 350.0 | 383.7 | 442.0 | 445.8 | 449.7 | 453.6 | 457.5 |
| Depreciation, % | 9.55 | 9.55 | 7.19 | 6.43 | 6.95 | 7.93 | 7.93 | 7.93 | 7.93 | 7.93 |
| EBIT | 295.3 | 492.0 | 770.0 | 1,127.8 | 1,213.6 | 1,057.0 | 1,066.2 | 1,075.5 | 1,084.8 | 1,094.2 |
| EBIT, % | 14.64 | 18.58 | 18.95 | 20.71 | 21.97 | 18.97 | 18.97 | 18.97 | 18.97 | 18.97 |
| Total Cash | 565.2 | 352.0 | 1,146.9 | 1,095.4 | 3,206.4 | 1,646.0 | 1,660.3 | 1,674.7 | 1,689.2 | 1,703.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 563.8 | 691.2 | 850.0 | 767.0 | 997.7 | 1,193.8 | 1,204.2 | 1,214.6 | 1,225.2 | 1,235.8 |
| Account Receivables, % | 27.96 | 26.11 | 20.92 | 14.09 | 18.06 | 21.43 | 21.43 | 21.43 | 21.43 | 21.43 |
| Inventories | 827.9 | 1,169.9 | 1,681.9 | 2,021.5 | 1,959.4 | 2,220.0 | 2,239.3 | 2,258.8 | 2,278.4 | 2,298.2 |
| Inventories, % | 41.05 | 44.19 | 41.39 | 37.13 | 35.47 | 39.85 | 39.85 | 39.85 | 39.85 | 39.85 |
| Accounts Payable | 349.3 | 530.3 | 640.0 | 842.2 | 610.4 | 887.2 | 894.9 | 902.7 | 910.5 | 918.4 |
| Accounts Payable, % | 17.32 | 20.03 | 15.75 | 15.47 | 11.05 | 15.92 | 15.92 | 15.92 | 15.92 | 15.92 |
| Capital Expenditure | -320.5 | -315.7 | -579.9 | -713.8 | -929.4 | -802.5 | -809.5 | -816.5 | -823.6 | -830.8 |
| Capital Expenditure, % | -15.89 | -11.93 | -14.27 | -13.11 | -16.83 | -14.4 | -14.4 | -14.4 | -14.4 | -14.4 |
| Tax Rate, % | 12.48 | 12.48 | 12.48 | 12.48 | 12.48 | 12.48 | 12.48 | 12.48 | 12.48 | 12.48 |
| EBITAT | 244.7 | 416.2 | 655.4 | 941.2 | 1,062.1 | 895.4 | 903.2 | 911.0 | 919.0 | 926.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -925.6 | 64.7 | -193.1 | 523.0 | 116.0 | 354.9 | 517.5 | 522.0 | 526.6 | 531.1 |
| WACC, % | 5.27 | 5.27 | 5.27 | 5.27 | 5.28 | 5.27 | 5.27 | 5.27 | 5.27 | 5.27 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 2,091.1 | |||||||||
| Long Term Growth Rate, % | 3.50 | |||||||||
| Free cash flow (T + 1) | 550 | |||||||||
| Terminal Value | 31,004 | |||||||||
| Present Terminal Value | 23,979 | |||||||||
| Enterprise Value | 26,070 | |||||||||
| Net Debt | -2,479 | |||||||||
| Equity Value | 28,549 | |||||||||
| Diluted Shares Outstanding, MM | 891 | |||||||||
| Equity Value Per Share | 32.05 |
What You Will Receive
- Authentic Zhejiang Jiuzhou Data: Preloaded financials – including revenue and EBIT – derived from actual and projected figures.
- Comprehensive Customization: Modify all essential parameters (yellow cells) such as WACC, growth rates, and tax percentages.
- Immediate Valuation Adjustments: Automatic recalculations to assess the effect of changes on the fair value of Zhejiang Jiuzhou Pharmaceutical (603456SS).
- Flexible Excel Template: Designed for quick modifications, scenario analysis, and in-depth forecasting.
- Efficient and Precise: Avoid the hassle of building models from scratch while ensuring accuracy and adaptability.
Key Features
- Comprehensive Historical Data for Zhejiang Jiuzhou Pharmaceutical (603456SS): Pre-filled with the company's past financial performance and future projections.
- Customizable Financial Inputs: Tailor revenue growth, profit margins, discount rates, tax rates, and capital expenditures to fit your analysis.
- Interactive Valuation Model: Automatically recalculates Net Present Value (NPV) and intrinsic value based on your specified parameters.
- Forecast Scenario Analysis: Develop various forecasting scenarios to evaluate different valuation possibilities.
- User-Friendly Interface: Intuitive design catering to both seasoned professionals and newcomers.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review the pre-filled data for Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456SS) (historical and projected).
- Step 3: Modify the key assumptions (highlighted in yellow) based on your analysis.
- Step 4: Observe the automatic updates for the intrinsic value of Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456SS).
- Step 5: Utilize the results for your investment decisions or reporting purposes.
Why Opt for This Financial Tool?
- Precision: Utilizes authentic Zhejiang Jiuzhou Pharmaceutical Co., Ltd financial data for reliable results.
- Adaptability: Tailored for users to easily experiment with and adjust various inputs.
- Efficiency: Avoid the complexities of creating a financial model from the ground up.
- Expert-Level: Crafted with the accuracy and functionality that CFOs appreciate.
- Intuitive: Simple to navigate, perfect for those without extensive financial modeling skills.
Who Can Benefit from This Product?
- Investors: Evaluate the valuation of Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456SS) prior to making stock transactions.
- CFOs and Financial Analysts: Optimize valuation processes and test financial forecasts.
- Startup Founders: Gain insights into the valuation methods used for established companies like Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456SS).
- Consultants: Provide expert valuation reports for your clients.
- Students and Educators: Utilize real-world examples to practice and teach valuation strategies.
Contents of the Template
- Thorough DCF Model: Editable framework featuring in-depth valuation calculations.
- Current Market Data: Zhejiang Jiuzhou Pharmaceutical’s historical and projected financials pre-included for comprehensive analysis.
- Adjustable Parameters: Modify WACC, growth rates, and tax considerations to explore different scenarios.
- Detailed Financial Statements: Complete annual and quarterly reports for enhanced insights.
- Essential Ratios: Integrated analysis of profitability, operational efficiency, and financial leverage.
- User-Friendly Dashboard with Visual Outputs: Graphs and tables designed for clear and actionable results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.